Free Trial

James Shin Analyst Performance

Analyst at Deutsche Bank Aktiengesellschaft

James Shin is a stock analyst at Deutsche Bank Aktiengesellschaft in the medical sector, covering 4 publicly traded companies. Over the past year, James Shin has issued 4 stock ratings, including buy and hold recommendations. While full access to James Shin's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights James Shin's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
4 Last 0 Years
Buy Recommendations
75.00% 3 Buy Ratings
Companies Covered
4 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy75.0%3 ratings
Hold25.0%1 ratings
Sell0.0%0 ratings

Out of 4 total stock ratings issued by James Shin at Deutsche Bank Aktiengesellschaft, the majority (75.0%) have been Buy recommendations, followed by 25.0% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NYSE
50.0% of companies on NYSE
2 companies
NASDAQ
50.0% of companies on NASDAQ
2 companies

James Shin, an analyst at Deutsche Bank Aktiengesellschaft, currently covers 4 companies listed on NYSE and NASDAQ, with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Medical
4 companies
100.0%

James Shin of Deutsche Bank Aktiengesellschaft specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
LARGE CAP PHARMA
2 companies
50.0%
MED - BIOMED/GENE
2 companies
50.0%

James Shin's Ratings History at Deutsche Bank Aktiengesellschaft

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
8/11/2025Lower Price Target$640.50$900.00Buy
Immatics N.V. stock logo
IMTX
Immatics
5/28/2025Initiated Coverage$5.05$10.00Buy
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2/18/2025Downgrade$83.01$105.00Hold
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2/18/2025Upgrade$104.08$120.00Buy